logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

TENFU (06868) spent 5460 Hong Kong dollars to repurchase 2000 shares on December 19th.

date
18:05 19/12/2025
avatar
GMT Eight
Tianfu (06868) announced the repurchase of 2000 shares for 5460 Hong Kong dollars on December 19, 2025.
TENFU (06868) announced that on December 19, 2025, it spent 5460 Hong Kong dollars to repurchase 2000 shares.
Related Articles
China Stock
Shanghai Kinlita Chemical (300225.SZ) is planning to sell 34% equity stake in its affiliated company, Yitaiji Technology, to optimize asset allocation.
China Stock
Yifang Biotechnology (688382.SH) intends to launch a restricted stock incentive plan for 2025.
HK Stock
Jiangsu Hengrui Pharmaceuticals (01276): HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets have been approved to conduct clinical trials.
Shanghai Kinlita Chemical (300225.SZ) is planning to sell 34% equity stake in its affiliated company, Yitaiji Technology, to optimize asset allocation.
China Stock
Yifang Biotechnology (688382.SH) intends to launch a restricted stock incentive plan for 2025.
China Stock
Jiangsu Hengrui Pharmaceuticals (01276): HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets have been approved to conduct clinical trials.
HK Stock
RECOMMEND
Academy Awards to Stream Exclusively on YouTube Beginning 2029
Academy Awards to Stream Exclusively on YouTube Beginning 2029
icon
18/12/2025
Western Food Chains Turn to Local Private Equity to Accelerate Growth in China
Western Food Chains Turn to Local Private Equity to Accelerate Growth in China
icon
18/12/2025
Hainan Island Customs Closure: More Than Just A “Shopping Paradise”?
Hainan Island Customs Closure: More Than Just A “Shopping Paradise”?
icon
18/12/2025
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.